Aquestive Therapeutics (AQST) Equity Average (2018 - 2025)
Historic Equity Average for Aquestive Therapeutics (AQST) over the last 8 years, with Q3 2025 value amounting to -$38.3 million.
- Aquestive Therapeutics' Equity Average rose 519.17% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.3 million, marking a year-over-year increase of 519.17%. This contributed to the annual value of -$83.3 million for FY2024, which is 2594.99% up from last year.
- Aquestive Therapeutics' Equity Average amounted to -$38.3 million in Q3 2025, which was up 519.17% from -$66.8 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Equity Average ranged from a high of -$35.9 million in Q2 2024 and a low of -$113.9 million during Q1 2023
- Over the past 5 years, Aquestive Therapeutics' median Equity Average value was -$71.2 million (recorded in 2021), while the average stood at -$75.1 million.
- Per our database at Business Quant, Aquestive Therapeutics' Equity Average crashed by 27213.83% in 2021 and then surged by 6675.1% in 2024.
- Quarter analysis of 5 years shows Aquestive Therapeutics' Equity Average stood at -$71.2 million in 2021, then crashed by 58.88% to -$113.2 million in 2022, then increased by 7.49% to -$104.7 million in 2023, then soared by 49.59% to -$52.8 million in 2024, then increased by 27.35% to -$38.3 million in 2025.
- Its last three reported values are -$38.3 million in Q3 2025, -$66.8 million for Q2 2025, and -$60.5 million during Q1 2025.